Abstract: Mixtures of salts to dissolve cellulose. The present invention refers to a composition based in a eutectic mixture of imidazolium salts and natural biopolymers, in particular cellulose, its manufacturing process and method of use to obtain foils or films. The composition is based in a eutectic mixture of imidazolium salts with 0.1 to 50 wt % of biomass.

Abstract: The invention relates to a nanoparticle comprising: (i) between 60 wt.-% and 99 wt.-% sorbitan ester, relative to the total weight of the nanoparticle; (ii) a positively charged substance; and (iii) a miRNA. The invention also relates to the methods for producing same and to the uses thereof, particularly for therapeutic uses, such as cancer treatment.

Abstract: The present invention refers to pyridazin-3(2H)-one derivatives of general structure I, II and III, which are selective MAO-B inhibitors, and to the use thereof for preparing medicaments intended to treat disorders derived from MAO-B hyperactivity, particularly degenerative disorders of the central nervous system (CNS), such as Parkinson's disease (PD), Alzheimer's disease (AD) and other dementias. These are pyridazin-3(2H)-one derivatives having dithiocarbamate moieties bonded to position 4, 5 or 6 through an alkyl chain of variable length (n=1, 2, 3). This invention is also directed to the preparation of said compounds.

Abstract: The present invention refers to a novel screening method for transfection employing novel acryloyl based amphiphilic polymers.

Abstract: The invention is based on the identification of the minimum region of the avian Orthoreovirus muNS protein which is capable of forming inclusions as well as on the identification of specific regions of the muNS protein showing capacity to associate with the inclusions formed by muNS. The identification of said regions allows developing methods for purifying recombinant polypeptides as well as methods for detecting the interaction between two polypeptides of interest.

Abstract: A system for administering biologically active substances produced by foaming techniques using compressed gases or supercritical fluids relates to a porous system containing biologically active substances. The system includes a polymer matrix of poly(D,L-lactic-co-glycolic acid) or a polymer mixture containing poly(D,L-lactic-co-glycolic acid) of an intrinsic viscosity of less than 0.5 dL/g with other biodegradable synthetic or semisynthetic polyesters, a release-regulating component (starch and derivatives), and at least one biologically active substance. The matrix is biodegradable with a solid or semisolid consistency and a homogeneous appearance. A method for producing these systems using foaming with compressed fluids, and the use for the production of implants and scaffolds having this system are also disclosed. Optionally, a porogenic agent can be used for the formation of macropores by thermal decomposition.

Abstract: The present invention refers to pyridazin-3(2H)-one derivatives of general structure I, II and III, which are selective MAO-B inhibitors, and to the use thereof for preparing medicaments intended to treat disorders derived from MAO-B hyperactivity, particularly degenerative disorders of the central nervous system (CNS), such as Parkinson's disease (PD), Alzheimer's disease (AD) and other dementias. These are pyridazin-3(2H)-one derivatives having dithiocarbamate moieties bonded to position 4, 5 or 6 through an alkyl chain of variable length (n=1, 2, 3). This invention is also directed to the preparation of said compounds.

Abstract: The present invention generally relates to particles, including nanoparticles, for example, for drug delivery or other applications. Certain aspects of the present invention are generally directed to particles, such as nanoparticles, comprising an inner portion and a coating. The inner portion may contain insulin or other therapeutic molecules for delivery to a living organism. In some cases, the molecules may be electrostatically complexed with an oppositely-charged peptide, such as an oligoarginine, or other species. The therapeutic molecules may also be water soluble. In some cases, the peptide may be conjugated to a hydrophobic portion, such as cholesterol, lauric acid, or a fatty acid chain. This hydrophobic modification may facilitate complex formation with the therapeutic molecule and the stability of the resulting complex. The complex typically is surrounded by a coating, which may protect the complex. For example, the coating may include polymers such as poly(glutamic acid) and poly(ethylene glycol).

Abstract: The invention relates to systems comprising homogenous nanoparticles having an average size of less than 1 micrometer and containing at least a sorbitan ester, a macrogol ester, a macrogol ether or a derivative of same and, optionally, at least one component derived from oxyethylene and/or at least one component having an electric charge (positive or negative). According to the invention, the components are incorporated in a single step consisting in mixing two solutions. The invention also relates to the use of said systems as medicines or medical devices, in tissue engineering or regenerative medicine, for cosmetic, hygienic or nutritional uses, and in surface coatings. The invention further relates to methods for preparing same.

Abstract: The present invention relates to nanosystems comprising metal atomic quantum clusters (AQCs) of at least two different sizes encapsulated in a cavity with an inner diameter less than or equal to 10 nm for the use thereof as luminescent nanosystems, particularly for the use thereof as fluorescent nanosystems; as well as the method for obtaining and detecting them. The invention also relates to the use of said luminescent nanosystems as a fluorescent probe, biomarker or contrasting agent.

Abstract: Integrated methanogenic anaerobic reactor and membrane bioreactor, and method for eliminating organic matter and nitrogen in urban or industrial wastewater, preferably with COD concentrations between 150 and 5000 mg/L and where the eliminations of total nitrogen that occur are between 15 and 50 mg/L, at temperatures above 15° C. The wastewater treatment takes place thanks to three stages of treatment: methanogenic anaerobic stage, anoxic stage with biofilms and suspended biomass and aerobic filtration stage with biofilms and suspended biomass.

Abstract: The present invention relates to compounds of pharmaceutical interest. More particularly, it relates to compounds of formula (I), to processes for obtaining thereof, to the intermediates of their synthesis and processes for obtaining the latter. The compounds of formula (I) have a certain affinity with the vitamin D receptor, they are active in a similar order to 1,25?-dihydroxyvitamin D3 (1,25D), with the advantage of producing less or no hypercalcemia.

Abstract: The present invention relates to the design and development of nanocapsule systems for the administration of active substances, wherein the nanocapsules of the system have a mean diameter less than 1 ?m and are characterized by comprising (a) a protamine shell, (b) an oily core, and one or more surfactants characterized by having a hydrophilic-lipophilic ratio greater than 8, provided that said surfactant is not a phospholipid.

Abstract: Stable atomic quantum clusters, AQCs, characterized by being composed of at least 500 metal atoms, its production process characterized by having a kinetic control and by maintaining a low concentration of reagents in the reaction medium, as well as the uses of these clusters as sensors (fluorescent, magnetic or chemical), electrocatalysts and as cytostatics and/or cytotoxics.

Abstract: The invention relates to a system for administering active ingredients, including nanocapsules comprising an oil, a cationic surfactant and a polymer selected from the group consisting of polyglutamic acid (PGA), polyglutamic-polyethyleneglycol acid (PGA-PEG), hyaluronic acid (HA) and polyasparagine (PAsn) or a combination of same and, optionally, an active ingredient, with the condition that when the polymer includes polyglutamic acid or polyglutamic-polyethyleneglycol acid (PGA-PEG) the active ingredient is not a didemnin or a tamandarin. The invention also relates to methods for obtaining said nanocapsule system, the pharmaceutical compositions thereof and the use of same in medicine.

Abstract: The present invention relates to hydroxyapatite doped with Fe2+ ions and Fe3+ ions which partially substitute the calcium ions in the crystal lattice. The hydroxyapatite is characterized by an intrinsic magnetism of 0.05 to 8 emu/g, measured by applying a magnetic field of 34 Oe, due to the presence of magnetic nano-domains in the crystal lattice of HA, given the limited amount of magnetic secondary phases present, less than about 3% by volume. The intrinsically magnetic hydroxyapatite can be loaded with biological substances selected in the group consisting of proteins, genes, stem cells, growth factors, vascularization factors, active substances and drugs, under the control of an external magnetic field, as a carrier and release agent for biological substances or drugs, as a contrast agent in diagnostics or for bone or osteocartilage regeneration.

Abstract: The invention relates to the use of stable atomic quantum clusters (AQC) with antimicrobial activity. The stable AQCs include at least 500 metal atoms (Mn, n<500), the metals being selected from among Au, Ag, Co, Cu, Pt, Fe, Cr, Pd, Ni, Rh, Pb or bi- or multi-metallic combinations thereof. Said AQCs are used as antimicrobial agents, antifungal agents and biocides at concentrations of the order of between 1 nM and 100 nM or more in relation to atoms of the corresponding metal. The antimicrobial activity is specific to both the type of metal and size of cluster used.

Abstract: The invention relates to conductive inks obtained by combining AQCs and metal nanoparticles. Atomic quantum clusters (AQCs), which melt at temperatures of less than 150° C., are used as low-temperature “flux” for the formulation of conductive inks. The combination of AQCs with bimodal and trimodal mixtures of nanoparticles of various sizes guarantees the elimination of free volumes in the final sintering of the nanoparticles in order to achieve electronic structures with very low resistivity (close to that of the bulk material) with low-temperature thermal treatments (<150° C.).

Abstract: Integrated methanogenic anaerobic reactor and membrane bioreactor, and method for eliminating organic matter and nitrogen in urban or industrial wastewater, preferably with COD concentrations between 150 and 5000 mg/L and where the eliminations of total nitrogen that occur are between 15 and 50 mg/L, at temperatures above 15° C. The wastewater treatment takes place thanks to three stages of treatment: methanogenic anaerobic stage, anoxic stage with biofilms and suspended biomass and aerobic filtration stage with biofilms and suspended biomass.

Abstract: The present invention relates to conjugates of formula (I) having colloidal stability in a medium, wherein NP is a gold, silver or platinum nanoparticle; L is a linker selected from the group consisting of formula (II), formula (III), and a stereoisomer of any of the formulas (II) and (III), which is attached to the nanoparticle NP through sulfur atoms; wherein the meanings of X, n, p, Y and s are further specified in the description; and A is a platinum (II) biradical selected from the group consisting of formula (IV), formula (V) and formula (VI) including any of the stereoisomers of all of them, wherein the biradical is optionally in the form of a salt and is attached to the linker L through the single bonded oxygen atoms of the carboxyl groups. It also relates to a process for the preparation of the conjugates of formula (I) and to pharmaceutical compositions containing them. The conjugates of the invention are used for the treatment of cancer.